Although subset analysis in the current study is underpowered, and its results should therefore be interpreted with caution, these soluble immune factors serve as better biomarkers for PD-1/PD-L1 blockade therapy in patients with a high tPD-L1 expression or with immune-reactive (hot) tumors characterized by a high level of CD8+ T cell infiltration in tumor tissue. This evidence concerns the gene CD274 and neoplasm.